MedTrace Logo

A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients

NCT05450601 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 249

Last updated 2024-03-05

No results posted yet for this study

Summary

A multicenter, randomized, double-blind, phase III study to evaluate the efficacy and safety of HCP2102 in patients with essential hypertension

Conditions

Interventions

DRUG

HCP2102-1

Take once daily for 2 weeks orally

DRUG

HPP2104-1

Placebo drug. Take once daily for 2 weeks orally

DRUG

HCP2102-2

Take once daily for 6 weeks orally

DRUG

HPP2104-2

Placebo drug. Take once daily for 6 weeks orally

DRUG

RLD2106-1

Take once daily for 2 weeks orally

DRUG

HPP2103-1

Placebo drug. Take once daily for 2 weeks orally

DRUG

RLD2106-2

Take once daily for 6 weeks orally

DRUG

HPP2103-2

Placebo drug. Take once daily for 6 weeks orally

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2023-12-11
Completion
2023-12-11

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05450601 on ClinicalTrials.gov